Lupin gets approval from USFDA for Tadalafil tablets

07 Feb 2019 Evaluate

Lupin has received approval for its Tadalafil tablets USP, 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Adcirca tablets, 20 mg.

The company's Tadalafil tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adcirca tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil tablets, 20 mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2082.55 -56.10 (-2.62%)
02-Feb-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1602.00
Dr. Reddys Lab 1170.25
Cipla 1293.60
Zydus Lifesciences 866.50
Lupin 2082.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×